海正药业（600267）(600267.SH)发布公告，近日，公司控股子公司浙江海正动物保健品有限公司(简 称"海正动保公司")收到中华人民共和国农业农村部核准签发的甲泼尼龙片(犬用)《新兽药注册证书》， 该新兽药产品正式获批五类新兽药。 本次海正动保公司甲泼尼龙片(犬用)产品获得五类《新兽药注册证书》，标志着上述产品已符合《兽药 管理条例》和《兽药注册办法》相关规定，有利于进一步推动公司在兽药板块的战略布局，提升公司市 场竞争力。 ...

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) announced that its subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the new veterinary drug registration certificate for Methylprednisolone Tablets (for dogs), officially classified as a Category 5 new veterinary drug [1] Group 1 - The new veterinary drug, Methylprednisolone Tablets (for dogs), is developed in collaboration with six other companies and is intended for the treatment of inflammatory and allergic diseases in dogs [1] - The drug can be used as part of treatment regimens for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation in the eyes/ears, as well as other inflammatory/allergic diseases effectively treated with glucocorticoids, including immune-mediated diseases [1]

Core Viewpoint - Haizheng Pharmaceutical's subsidiary, Zhejiang Haizheng Animal Health Products Co., has received approval for a new veterinary drug, Methylprednisolone Tablets (for dogs), marking a significant step in the company's strategic expansion in the veterinary medicine sector [1] Group 1 - The new veterinary drug product has been granted a Class V New Veterinary Drug Registration Certificate by the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] - The approval indicates that the product complies with the relevant regulations of the Veterinary Drug Administration and the Veterinary Drug Registration Measures [1] - This development is expected to enhance the company's market competitiveness in the veterinary medicine segment [1]

Core Viewpoint - Haizheng Pharmaceutical's subsidiary, Haizheng Animal Health, has received approval for a new veterinary drug, Methylprednisolone Tablets (for dogs), marking a significant step in the company's strategic positioning in the veterinary medicine sector [2]. Group 1 - The product, Methylprednisolone Tablets (for dogs), is intended for the treatment of canine inflammatory and allergic diseases [2]. - The approval was granted by the Ministry of Agriculture and Rural Affairs, indicating that the product meets relevant regulatory standards [2]. - The development of this product was a collaborative effort among Haizheng Animal Health and six other companies [2]. Group 2 - The new veterinary drug registration certificate signifies that the product is ready for production and market launch [2]. - Despite the approval, it is noted that there will be no significant short-term impact on the company's financial performance [2]. - This development is expected to enhance the company's competitiveness in the veterinary medicine market [2].

Group 1 - The core point of the article highlights the announcement by *ST Lvkang regarding its board meeting and the discussion of the employee stock ownership plan [1] - The company's revenue composition for the first half of 2025 is detailed, with veterinary medicine accounting for 61.79%, photovoltaic film for 26.1%, biopesticides for 5.99%, others for 2.83%, and food additives for 2.19% [1] - As of the report, *ST Lvkang has a market capitalization of 5.4 billion yuan [1] Group 2 - The article also mentions concerns regarding the financial practices of related parties, with allegations of mismanagement leading to significant financial losses for investors [1] - The company is facing potential delisting due to these financial issues, raising questions among shareholders about the whereabouts of their investments [1]

Group 1 - The core point of the article is that Tiankang Biological announced the acquisition of a 51% stake in Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd. during a board meeting held on December 11, 2025 [1] - The revenue composition of Tiankang Biological for the first half of 2025 is as follows: pig farming accounts for 32.2%, feed accounts for 27.51%, agricultural product processing accounts for 16.37%, corn storage accounts for 14.75%, and veterinary medicine accounts for 5.44% [1] - As of the report date, Tiankang Biological has a market capitalization of 9.5 billion yuan [1]

Core Insights - Chongqing Hanpei Biotechnology Co., Ltd. has completed a Pre-A round financing of tens of millions of yuan, marking the largest single financing case in the seed fund support project by the Chongqing Liangjiang Industry Group [1] - The financing indicates a significant breakthrough in the Chongqing government's seed fund efforts to cultivate early-stage technology projects and facilitate the transformation of scientific achievements [1] Company Overview - Hanpei Biotechnology focuses on the pet economy, which is projected to reach a market size of over 300 billion yuan in the urban pet medical market by 2024, with a year-on-year growth of 5.6% [3] - The company aims to address the supply-demand mismatch in the high-end pet medication market, where domestic products face challenges from international giants [3] Talent and Innovation - The core technical team of Hanpei Biotechnology consists of over 50% PhD holders and 70% master's degree holders, including leaders from major universities and national key project scientists [4] - The company has developed a long-acting antibiotic for pets, which has received national certification, and is working on next-generation antibiotic products [5] Market Position and Strategy - Hanpei Biotechnology is dedicated to creating a leading domestic platform for high-end veterinary drug innovation, focusing on first-in-class and best-in-class pet medications [6] - The company has over 20 new drug candidates in development, including three national class I new veterinary drugs, with a focus on various therapeutic areas [5] Government Support and Funding - The early investment from the Chongqing seed fund has provided a solid foundation for Hanpei Biotechnology, enabling technology validation and initial research [7] - The investment model of the seed fund has proven effective in reducing investment concerns from social capital, supporting over 50 projects across various cutting-edge industries [7] Future Prospects - With the influx of funds from the recent financing, Hanpei Biotechnology is accelerating the clinical development of innovative drugs for pet infections and gastrointestinal diseases, aiming to reshape the domestic pet pharmaceutical market [8]

Core Viewpoint - The research team led by Professor Wang Chengbao from Northwest A&F University has developed an inactivated vaccine for pigeon Newcastle disease (PN06 strain), which has officially received the national Class II new veterinary drug certificate, marking a significant breakthrough in the independent research and development of biological products for pigeons in China [1]. Group 1: Vaccine Development - The PN06 strain vaccine is the first domestically approved veterinary drug product that has not been formally marketed in China, representing a high innovation benchmark in the veterinary field due to the high development barriers and long cycles associated with vaccine biological products [1]. - The vaccine is designed to address the high morbidity and mortality rates associated with pigeon Newcastle disease, which has historically relied on chicken Newcastle disease vaccines with limited efficacy and frequent immunization failures [1]. Group 2: Research and Testing - Since 2016, the research team has screened advantageous strains from hundreds of disease samples across the country, successfully cultivating the PN06 strain with good immunogenicity after overcoming key technical challenges in virus culture purification and inactivation process optimization [1]. - The vaccine completed laboratory research in 2019 and underwent two years of clinical trials to verify its safety and effectiveness [1]. Group 3: Market Impact - The vaccine is suitable for all breeds and ages of pigeons, with minimal stress response post-vaccination and a protection rate exceeding 90%, along with a long-lasting immune duration [1]. - This development addresses the issues of high prices and mismatched strains associated with imported vaccines, filling a gap in the supply of high-quality domestic vaccines for pigeons [1]. Group 4: Industry Context - China has the largest scale of pigeon farming globally, but the disease prevention and control system remains weak [1]. - The research team has established the most comprehensive resource bank of pigeon source strains and bacterial strains in the country and plans to continue advancing the development of a series of pigeon vaccines and drugs [1].

Group 1 - The core point of the article is the announcement by *ST Lvkang regarding its board meeting and the composition of its revenue for the first half of 2025 [1] - The board meeting was held on December 8, 2025, to discuss the proposal for the temporary shareholders' meeting [1] - The revenue composition for *ST Lvkang in the first half of 2025 is as follows: veterinary medicine 61.79%, photovoltaic film 26.1%, biopesticides 5.99%, others 2.83%, and food additives 2.19% [1] Group 2 - As of the report, *ST Lvkang has a market capitalization of 5.7 billion yuan [1]

Core Viewpoint - The company has obtained a new veterinary drug registration certificate for a trivalent inactivated vaccine targeting Newcastle disease, avian influenza (H9 subtype), and avian adenovirus disease (I group 4) [1] Group 1: Regulatory Compliance - The vaccine registration is in accordance with the Veterinary Drug Management Regulations and the Measures for the Approval Number Management of Veterinary Drug Products [1] - The company is currently in the process of applying for the veterinary product approval number issued by the Ministry of Agriculture and Rural Affairs, which is required before the product can be marketed [1]